<DOC>
	<DOCNO>NCT00880230</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness Scuba™ stent subject symptomatic claudication rest pain angiographic confirmation de novo restenotic lesion common and/or external iliac artery .</brief_summary>
	<brief_title>Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent ( INTENSE )</brief_title>
	<detailed_description>Interventional revascularization strategy peripheral arterial disease currently available include surgical endovascular approach percutaneous transluminal angioplasty ( PTA ) , either stand-alone procedure placement stent . Cobalt-chromium ( CoCr ) alloy use safely manufacture surgical implant use contact blood , soft tissue bone 10 year . This study evaluate SCUBA™ peripheral balloon-expandable cobalt chromium tent system iliac artery .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>Presence de novo restenotic lesion ( ) , locate common external iliac artery ≥50 % stenosis Subject lifestyle limit claudication rest pain , ( Rutherford Becker scale [ clinical category ] 2 , 3 , 4 ) Target vessel reference diameter 5mm 10mm visual assessment Target lesion length &lt; 130mm Subject angiographic evidence patent femoral outflow artery target limb Subject provide write informed consent Subject able willing adhere require followup visit test Subject lesion Common Femoral Artery ( CFA ) , Profundal Femoral Artery ( PFA ) , Superficial Femoral Artery ( SFA ) would require staged procedure within 30 day index procedure ( either ) Target lesion ( ) adjacent , acute thrombus Target lesion ( ) highly calcify previously treat stent Subject preexist target iliac artery aneurysm perforation dissection target iliac artery Subject abdominal aortic aneurysm contiguous iliac artery target lesion Subject postsurgical stenosis anastomotic suture treatment native iliac vessel Subject vascular graft previously implant native iliac vessel Subject tissue loss RutherfordBecker clinical category 5 6 History neutropenia ( WBC &lt; 3,000/mm3 ) , coagulopathy , thrombocytopenia ( platelet count &lt; 80,000/uL ) International Normalized ratio ( INR ) great 1.5 Serum creatinine great 2.5 mg/dL Subject know bleeding hypercoagulability disorder significant anemia ( Hb &lt; 8.0 g/dL ) correct Subject participate investigational study new drug , biologic , device time study screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Iliac Artery Stenting</keyword>
	<keyword>Peripheral Artery Disease</keyword>
</DOC>